Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
C-Max (Cerebrolysin variant) vs Pinealon
An educational, source-based comparison of C-Max (Cerebrolysin variant) and Pinealon — how each peptide works, what it's researched for, and what to know before going deeper.
Concentrated neuropeptide fraction for cognitive support research.
A concentrated fraction of cerebrolysin containing specific neuropeptide sequences. Research suggests enhanced delivery of neurotrophic factors supporting synaptic maintenance and neurogenesis.
- Post-stroke cognitive recovery
- Vascular cognitive impairment
- Traumatic brain injury rehabilitation
- • Not FDA-approved in the US; approved in select countries.
- • Requires medical supervision for IV administration.
Short peptide bioregulator researched for cognition and aging.
A synthetic tripeptide (Glu-Asp-Arg) in the Khavinson short-peptide bioregulator family. Research from Russian gerontology groups proposes gene-expression modulation linked to neuronal survival and cognitive performance.
- Cognitive aging in rodent models
- Neuronal apoptosis under oxidative stress
- Circadian and neuroendocrine regulation
- • Most evidence from Russian literature; independent replication is limited.
- • Not FDA-approved.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| C-Max (Cerebrolysin variant) | Concentrated neuropeptide fractions in stroke rehabilitation | Neurorehabilitation and Neural Repair | 2018 | Improved functional outcomes in post-stroke patients receiving neuropeptide therapy. |
| Pinealon | Pinealon protects neurons from oxidative stress | Bulletin of Experimental Biology and Medicine | 2012 | Reduced apoptosis markers in cultured neurons under H2O2 challenge. |
Side-effect & safety grid
- Not FDA-approved in the US; approved in select countries.
- Requires medical supervision for IV administration.
- Most evidence from Russian literature; independent replication is limited.
- Not FDA-approved.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
C-Max (Cerebrolysin variant) vs Pinealon — Key differences
- Class: C-Max (Cerebrolysin variant) is classified as Nootropic · Neurotrophic, while Pinealon is Bioregulator · Neuroprotection.
- Primary research focus: C-Max (Cerebrolysin variant) — post-stroke cognitive recovery; Pinealon — cognitive aging in rodent models.
- Tag: Cognition vs Cognition · Longevity.